Spinal cord injury target-immunotherapy with TNF-α autoregulated and feedback-controlled human umbilical cord mesenchymal stem cell derived exosomes remodelled by CRISPR/Cas9 plasmid
Source abstract
Abstract
Human umbilical cord mesenchymal stem cell (hucMSC) derived exosomes (EXOs) have been investigated as a new treatment for spinal cord injury (SCI) because of their anti-inflammatory, anti-apoptotic, angiogenesis-promoting, and axonal regeneration properties. The CAQK peptide found in the brains of mice and humans after trauma has recently been found to specifically bind to the injured site after SCI. Thus, we developed a nanocarrier system called EXO-C@P based on hucMSC exosomes remodelled by the CRISPR/Cas9 plasmid to control inflammation and modified by the CAQK peptide. EXO-C@P was shown to effectively accumulate at the injury site and saturate the macrophages to significantly reduce the expression of inflammatory cytokines in a mouse model of SCI. Moreover, EXO-C@P treatment improved the performance of mice in behavioural assessments and upregulated soluble tumour necrosis factor receptor-1 (sTNFR1) in serum and at the trauma site after SCI surgery, but lowered the proportion of iNOS+ cells and the concentration of proinflammatory factors. In conclusion, EXO-C@P provides an effective alternative to multiple topical administration and drug delivery approaches for the treatment of SCI. STATEMENT OF SIGNIFICANCE: SCI is a serious disease characterised by a high incidence, high disability rate, and high medical costs, and has become a global medical problem. Several studies have shown that the inflammatory response is the critical inducer of secondary injury after SCI. The inflammatory cytokine TNF-α is considered to be one of the most significant therapeutic targets for autoimmune diseases. Antibodies targeting TNF-α and sTNFR1 are capable of neutralising free TNF-α. In this study, exosomes in the CRISPR/Cas9 system were used to establish stem cells with an autoregulated and feedback-controlled TNF-α response, with these cells secreting sTNFR1, which neutralised TNF-α and antagonised the inflammation stimulated by TNF-α. Moreover, the plasmid was combined with CAQK, which targeted the injury site and promoted the recovery of SCI function.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Extracellular vesicles in disease · RNA Interference and Gene Delivery · Spinal Cord Injury Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (48)
Show source-provided references
1. Global neurotrauma research challenges and opportunities10.1038/nature16035 ↗
2. Restoring function after spinal cord injury: towards clinical translation of experimental strategies10.1016/S1474-4422(14)70144-9 ↗
3. Inflammogenesis of secondary spinal cord injury10.3389/fncel.2016.00098 ↗
4. Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord10.1046/j.1460-9568.1999.00792.x ↗
5. Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury10.1016/j.neuroscience.2008.07.001 ↗
6. Programmed death 1 deficiency induces the polarization of macrophages/microglia to the M1 phenotype after spinal cord injury in mice10.1007/s13311-013-0254-x ↗
7. The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury10.1016/j.neuron.2015.01.013 ↗
8. Polarized macrophages have distinct roles in the differentiation and migration of embryonic spinal-cord-derived neural stem cells after grafting to injured sites of spinal cord10.1038/mt.2015.46 ↗
9. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE)
10. The long-term outcome of anti-TNF alpha therapy in perianal Crohn's disease10.1007/s10151-016-1578-4 ↗
11. Genome engineering of stem cells for autonomously regulated, closed-loop delivery of biologic drugs10.1016/j.stemcr.2017.03.022 ↗
12. New and old diagnostic markers of meningitis in cerebrospinal fluid (CSF)10.1016/S0361-9230(03)00092-3 ↗
13. Transplanted neural stem/precursor cells instruct phagocytes and reduce secondary tissue damage in the injured spinal cord10.1093/brain/awr339 ↗
14. Effects of etanercept and minocycline in a rat model of spinal cord injury10.1016/j.ejpain.2008.08.001 ↗
15. Gammadelta T cells provide the early source of IFN-gamma to aggravate lesions in spinal cord injury10.1084/jem.20170686 ↗
16. Anti-TNIF therapy in the injured spinal cord10.1016/j.tips.2010.11.009 ↗
17. hucMSC derived exosomes promote functional recovery in spinal cord injury mice via attenuating inflammation10.1016/j.msec.2018.04.006 ↗
18. Exogenous DNA loading into extracellular vesicles via electroporation is size-dependent and enables limited gene delivery10.1021/acs.molpharmaceut.5b00364 ↗
19. Mesenchymal stem cell and derived exosome as small RNA carrier and immunomodulator to improve islet transplantation10.1016/j.jconrel.2016.07.044 ↗
20. Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors10.1182/bloodadvances.2017010181 ↗
21. Bioinspired and biomimetic systems for advanced drug and gene delivery10.1016/j.jconrel.2018.08.033 ↗
22. Exosomes: natural nanoparticles as bio shuttles for RNAi delivery10.1016/j.jconrel.2018.10.001 ↗
23. Non-viral CRISPR/Cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA10.1002/anie.201610209 ↗
24. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication10.1038/s41556-018-0250-9 ↗
25. SiRNA delivery with exosome nanoparticles10.1038/nbt.1830 ↗
26. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes10.1016/j.jconrel.2014.12.013 ↗
27. A peptide for targeted, systemic delivery of imaging and therapeutic compounds into acute brain injuries10.1038/ncomms11980 ↗
28. Novel multi-drug delivery hydrogel using scar-homing liposomes improves spinal cord injury repair10.7150/thno.26717 ↗
29. Synthesis and characterization of a silica-based drug delivery system for spinal cord injury therapy10.1007/s40820-019-0252-6 ↗
30. Simple, and reproducible method for the isolation of mesenchymal stromal cells from Wharton's jelly without enzymatic treatment10.1089/scd.2010.0260 ↗
31. Basso mouse scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains10.1089/neu.2006.23.635 ↗
32. Relevance of helicobacter pylori genotypes in gastric pathology and its association with plasma malondialdehyde and nitric oxide levels10.1007/s10787-010-0031-y ↗
33. Comprehensive analysis of neurobehavior associated with histomorphological alterations in a chronic constrictive nerve injury model through use of the cat walk XT system10.3171/2013.9.JNS13353 ↗
34. Required growth facilitators propel axon regeneration across complete spinal cord injury10.1038/s41586-018-0467-6 ↗
35. A novel role of phospholipase A2 in mediating spinal cord secondary injury10.1002/ana.20798 ↗
36. Macrophage MSR1 promotes the formation of foamy macrophage and neuronal apoptosis after spinal cord injury10.1186/s12974-020-01735-2 ↗
37. Conditional ablation of myeloid TNF improves functional outcome and decreases lesion size after spinal cord injury in mice
38. Sequential mRNA expression for immediate early genes, cytokines, and neurotrophins in spinal cord injury10.1089/neu.2000.17.203 ↗
39. Macrophage activation and its role in repair and pathology after spinal cord injury10.1016/j.brainres.2014.12.045 ↗
40. Sequential expression of macrophage anti-microbial/inflammatory and wound healing markers following innate, alternative and classical activation10.1111/j.1365-2249.2009.04086.x ↗
41. Parthenolide promotes the repair of spinal cord injury by modulating M1/M2 polarization via the NF-kappa B and STAT 1/3 signaling pathway
42. Shedding light on the cell biology of extracellular vesicles10.1038/nrm.2017.125 ↗
43. Label-free sensing of exosomal MCT1 and CD147 for tracking metabolic reprogramming and malignant progression in glioma10.1126/sciadv.aaz6119 ↗
44. Systemic administration of exosomes released from mesenchymal stromal cells attenuates apoptosis, inflammation, and promotes angiogenesis after spinal cord injury in rats10.1089/neu.2017.5063 ↗
45. Chromatographically isolated CD63(+) CD81(+) extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI10.1073/pnas.1522297113 ↗
46. Exosomes derived from miR-133b-modified mesenchymal stem cells promote recovery after spinal cord injury
47. Exosomes derived from bone mesenchymal stem cells repair traumatic spinal cord injury by suppressing the activation of A1 neurotoxic reactive astrocytes10.1089/neu.2018.5835 ↗
48. Microglia and macrophage metabolism in CNS injury and disease: the role of immunometabolism in neurodegeneration and neurotrauma10.1016/j.expneurol.2020.113310 ↗